What Happened to Clinical Failure Rates Over the Decades?
Clinical trial failure rates have remained persistently high over the decades, with only a small fraction of investigational drugs successfully navigating all phases to market approval. While historically around 10-14% of drugs entering Phase I reached approval, recent analyses show this figure has stabilized or even slightly declined to around 6.7-7.9% by 2023, driven by increasing biological complexity and more stringent early-stage evaluations. However, advancements in adaptive trial designs, artificial intelligence, personalized medicine, and gene-editing technologies like CRISPR are beginning to offer new avenues for improving efficiency and success in the mid-2020s.
Quick Answer
Clinical trial failure rates have consistently been high, with the overall likelihood of approval for new drugs entering Phase I hovering around 6.7% to 7.9% in recent years (2014-2023). Phase II remains the most significant hurdle, with success rates often below 30%. Key drivers of failure include lack of efficacy and unexpected toxicity, contributing to the spiraling cost of drug development, estimated at over $2.6 billion per approved drug. As of 2026, the industry is increasingly leveraging adaptive trial designs, AI, and personalized medicine with biomarkers to improve patient selection and trial efficiency, showing promise in specific therapeutic areas like oncology and rare diseases, and potentially stabilizing or improving success rates in the coming years.
📊Key Facts
📅Complete Timeline15 events
Persistent High Failure Rates and 'Eroom's Law'
The pharmaceutical industry consistently faced high clinical trial failure rates, with the number of new drugs approved per dollar spent on R&D halving roughly every nine years, a trend known as 'Eroom's Law'.
Drug Development Cost Estimated at $802 Million
The estimated cost of developing a new drug was approximately $802 million (adjusted for inflation), a figure that would significantly increase in subsequent years.
High Phase I Success Rates (Over 75%)
During this period, Phase I clinical trials, primarily focused on safety, exhibited success rates exceeding 75%. This trend would later decline due to earlier efficacy evaluations.
Steepest Decline in Clinical Success Rates
The industry experienced its steepest decline in clinical success rates, coinciding with major pharmaceutical companies undergoing large-scale transformations and pipeline pruning efforts.
Overall LOA at 7.9%; Phase II Remains Major Hurdle
An analysis of this decade showed the overall likelihood of approval from Phase I for all developmental candidates was 7.9%, with Phase II remaining the largest hurdle at a 28.9% success rate.
Cost of Drug Development Exceeds $2.5 Billion
The Tufts Center for the Study of Drug Development estimated the cost to develop a new prescription medicine that gains marketing approval had risen to $2.6 billion, including failures and capitalized costs.
Attrition Rates Show Signs of Decreasing
Studies indicated that attrition rates were decreasing at all stages of clinical research, though they remained higher than in the 1990s, suggesting some improvements in R&D efficiency.
CRISPR-Cas9 Nobel Prize Fuels Gene Editing Research
Jennifer Doudna and Emmanuelle Charpentier were awarded the Nobel Prize in Chemistry for their work on CRISPR-Cas9 gene editing, significantly boosting interest and investment in gene therapy clinical trials.
Overall LOA Drops to 6.7% (2014-2023 Data)
Data from 2014-2023 revealed that the average likelihood of approval for a new Phase I drug had fallen to an all-time low of 6.7%, with Phase I success rates dropping below 40% from over 75% in 2006-2008.
Adaptive Clinical Trials Gain Regulatory Acceptance
Regulatory agencies, including the FDA, provided guidance for adaptive trial designs, acknowledging their potential to accelerate drug development, enhance patient safety, and improve efficiency.
Patient Recruitment and Retention Highlighted as Key Success Factors
Factors such as patient recruitment and retention, protocol design, and technological advances were identified as crucial for clinical trial success, especially in the post-pandemic recovery period.
Personalized Oncology Significantly Improves Treatment Success
A clinical trial led by UC San Diego School of Medicine demonstrated that tailoring multi-drug treatments to a patient's unique tumor DNA significantly enhanced treatment success in advanced cancers.
AI Poised to Deliver Real Value in Clinical Trials
Experts predict 2026 as a turning point for AI in clinical trials, moving from exploration to execution, with AI-powered simulations and richer data reshaping trial design and improving patient experience.
CRISPR Therapeutics Reports Positive Clinical Data
CRISPR Therapeutics announced positive Phase 1 data for CAR-T cells in autoimmune conditions and promising Phase 2 data expected later in the year for CTX611, highlighting ongoing advancements in gene-editing therapies.
Biomarker-Driven Stratification Boosts Oncology Approval Odds
Analysis confirms that oncology programs utilizing biomarkers for patient stratification achieve a 10.7% probability of success, significantly higher than the 1.6% for unselected programs, underscoring the impact of precision medicine.
🔍Deep Dive Analysis
The landscape of clinical trial success rates has been characterized by persistent challenges and high attrition over several decades, a phenomenon often referred to as 'Eroom's Law' (Moore's Law spelled backward), indicating that drug discovery becomes progressively harder and more expensive over time. Historically, the overall probability of a drug progressing from Phase I to market approval has ranged between 10% and 14%. However, recent analyses covering the period from 2014 to 2023 indicate a slight decline, with the average likelihood of approval (LOA) for new Phase I drugs falling to 6.7%. The Phase II stage consistently represents the greatest hurdle, with success rates often below 30%, as this is the first time a drug's efficacy is tested in a meaningful patient population.
The primary reasons for these high failure rates are consistently identified as a lack of efficacy and unexpected toxicity. These failures contribute significantly to the escalating cost of drug development, which the Tufts Center for the Study of Drug Development estimated at $2.6 billion per approved new prescription medicine as of 2021, a figure that includes the high cost of drug failures and capitalized costs over lengthy development cycles. This substantial financial burden underscores the critical need for improved efficiency and higher success rates in the biopharmaceutical industry. The complexity of diseases, evolving regulatory demands, and the sheer scale of modern clinical trials have further exacerbated these challenges.
Over the past two decades, several turning points and methodological shifts have emerged in response to these challenges. The early 2000s saw a decline in success rates, with the steepest drop observed between 2007 and 2010, partly due to large-scale pharmaceutical company transformations and pipeline pruning. However, the increasing use of biomarkers for patient preselection has shown to significantly improve success rates, particularly in Phase II, where programs with biomarkers have nearly double the likelihood of approval. The rise of biologics also demonstrated consistently higher cumulative success rates compared to small molecules between 1996 and 2014. More recently, adaptive trial designs, which allow for modifications based on accumulating data, have gained traction and regulatory acceptance, promising to shorten development times, reduce sample sizes, and improve efficiency and ethical considerations.
The mid-2020s are witnessing a technological revolution aimed at tackling clinical trial failures. Artificial intelligence (AI) and machine learning (ML) are rapidly being integrated across the entire trial lifecycle, from hypothesis generation and protocol design to patient recruitment, monitoring, and data analysis. In 2026, 92% of organizations plan to increase their AI investment, expecting significant returns in areas like task automation and data cleaning. Personalized medicine, driven by genomic sequencing and biomarker analysis, is also proving highly effective. A January 2026 study demonstrated that individualizing multi-drug treatments based on a patient's tumor DNA significantly enhanced treatment success in advanced cancers. Furthermore, gene-editing technologies like CRISPR are showing promising results in clinical trials for genetic disorders and autoimmune conditions, with over 100 CRISPR-based trials ongoing worldwide as of early 2026.
As of July 2026, while the overall clinical failure rates remain a significant concern for the biopharma industry, the concerted efforts in adopting advanced technologies and patient-centric approaches are creating a more optimistic outlook. The focus is shifting towards smarter, more efficient trial designs that leverage data to make early, informed decisions, thereby reducing costly late-stage failures. The integration of AI, precision medicine, and gene therapies is not only improving the chances of success for novel treatments but also reshaping the entire drug development paradigm, aiming to deliver more effective and safer therapies to patients faster.
What If...?
Explore alternate histories. What if Clinical Failure Rates Over the Decades made different choices?